共 35 条
- [1] Fleming TR(2017)Data monitoring committees: promoting best practices to address emerging challenges Clin Trials 14 115-123
- [2] DeMets DL(2006)Committee for Medicinal Products for Human Use (CHMP) guideline on data monitoring committees Stat Med 25 1639-1645
- [3] Roe MT(2015)Data and safety monitoring of Danhong injection in W clinical trials Journal of Chinese Pharmaceutical ences 50 375-378
- [4] Wittes J(2016)Data monitoring committees-expect the unexpected N Engl J Med 375 1365-1371
- [5] Calis KA(1999)ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group Stat Med 18 1905-1942
- [6] Vora AN(2006)Operating characteristics of sample size reestimation with futility stopping based on conditional power Stat Med 25 3348-3365
- [7] Wang L(1992)Monitoring clinical trials with a conditional probability stopping rule Stat Med 11 659-672
- [8] Liu J(2014)Comparative effectiveness of Di’ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina Sci Rep 4 7058-undefined
- [9] Dang HX(2015)Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial Trials 16 561-undefined
- [10] Wang Z(2015)Danhong Injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial Trials 16 474-undefined